Publication Topic

Perreault L, Rasouli N, Sanogo F, Movva N, Bylsma L, Suh M, Reichert H, Donsmark M, Girguis M, Frankenfeld C. A meta-analysis of persistence and adherence to glucagon-like peptide 1-based treatments among patients with type 2 diabetes in the United States. Abstract/Poster 1691-P, American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, June 7, 2026.

Agarwal I, Frankenfeld C, Schernhammer E, Strohmaier S, Fleisch AF, Rich-Edwards J, Tobias DK. 2026. Rotating night shift work, gestational diabetes and risk of type 2 diabetes among US nurses. Occup Env Med; doi: 10.1136/oemed-2025-110594. Online ahead of print January 28. PMID: 41605642.

Frankenfeld CL, Movva N, Reichert H, Doepker C. Dietary intake and nutrient adequacy differ across GLP-1RA users based on length of GLP1-RA use. Poster 268, ObesityWeek 2025, Atlanta, GA, November 5, 2025.

Movva N, Girguis M, Bylsma L, Saleem N, Grasic K, Suh M, Pastula S, Frankenfeld C. 2025. Systematic literature review of glucagon-like peptide 1 (GLP-1) receptor agonist use among type 2 diabetes in the United States. PROSPERO 2025:CRD4202564618. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025646418.

Davison NJ, Guthrie NL, Medland S, Lupinacci P, Nordyke RJ, Berman MA. 2024. Cost-effectiveness analysis of a prescription digital therapeutic in Type 2 diabetes. Adv Ther 41(2):806-825; doi: 10.1007/s12325-023-02752-2. PMID: 38170435.

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Torres KA. Diabetes specific ONS led to a blunted postprandial glucose response and a 26% reduction in peak blood glucose levels compared to a standard ONS. Presented at FNCE 2022 Food & Nutrition Conference & Expo, Orlando, FL, October 2022.

Klosterbuer A, Cekola P, Neutel JM, Jiang X, Cohen SS, Araujo Torres K. 2021. Effect of diabetes-specific oral nutritional supplements on postprandial glycemic response in adults with type 2 diabetes mellitus. Poster presented at ASPEN Nutrition Science & Practice Conference, March 2021.

Elbeddini A, Tayefehchamani Y, Davey M, Gallinger J, Hooda N, Aly A, Erickson D, Lee S. 2021. Fournier’s gangrene with dapagliflozin in a rural hospital: A case report. BMJ Case Rep 14(2):e237784; doi: 10.1136/bcr-2020-237784. PMID: 33526523.

Nordyke RJ, Appelbaum K, Berman MA.  2019. Estimating the impact of novel digital therapeutics in Type 2 diabetes and hypertension: Health economic analysis. J Med Internet Res 21(10):e15814; doi: 10.2196/15814. PMID: 31937249.

Brixner D, Ermakova A, Xiong Y, Sieradzan R, Sacks NC, Cyr PL, Taylor S. 2019. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: A retrospective cohort study. Clin Therapeut 41(2):303–313; doi: 10.1016/j.clinthera.2018.12.014; PMID: 30709610.

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization for multiple-daily injections (MDI) with basal and bolus insulin therapy versus non-MDI therapy in patients with Type 2 diabetes. Poster presentation at Academy of Managed Care Pharmacy Annual Research Meetings, Boston, MA, 2018.

Ludden T, Ermakova A, Xiong Y, Cyr PL, Sieradzan R, Sacks NC, Taylor SD. Comparison of healthcare resource utilization and clinical status among Type 2 diabetes patients using multiple-daily injection (MDI) insulin therapy vs. non-MDI therapy. ISPOR 23^rd Annual Conference, Baltimore MD, 2018.

Sacks NC, Liu Y, Sanyal A, DeFronzo R, Bhatt DL, Caplan, J… Cyr PL, et al. The economic burden of insulin resistance, obesity, and cardiovascular disease in Medicare beneficiaries 65 years of age and older. American Heart Association Scientific Sessions, Anaheim CA, 2017.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, … Dingley KH, et al. 2016. Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes. ACS Med Chem Lett 7 (12):1107–1111; doi: 10.1021/acsmedchemlett.6b00314. PMID: 27994747.

Sacks NC, Cabral HJ, Pizer SD, Burgess JF. 2016. Myopic and forward looking behavior in branded oral anti-diabetic consumption: An example from Medicare Part D. Health Econ 26(6):753-764; doi: 10.1002/hec.3355. PMID: 27150938.

Liu P, Hu Z, DuBois BG, Moyes CR, Hunter DN, Zhu C, … Dingley KH, et al. 2015. Design of potent and orally active GPR119 agonists for the treatment of type II diabetes. ACS Med Chem Lett 6(8):936–941; doi: 10.1021/acsmedchemlett.5b00207. PMID: 26288697.

Miller PE, Bylsma LC, Alexander DD. A review and meta-analysis of red meat consumption and type 2 diabetes. Presented at the Experimental Biology Conference, Boston, MA, April 2015.

Karchapati L, Bednar KJ, Adams DE, Wu Y, Mitter RS, Jordan MB, Hinerman JM, Herr AB, Ridgway WM. 2013. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J Autoimmun 47(Dec):94–103; doi: 10.1016/j.jaut.2013.09.002. PMID: 24145149.

Enayetallah AE, Ziemek D, Leininger MT, Randhawa R, Yang J, Manion TB, Mather DE,…, Greene N, et al. 2011. Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. PLoS One 6(11):e27009; doi: 10.1371/journal.pone.0027009. PMID: 22073239.